



Chinese American Hematologist and Oncologist Network (CAHON) 美国华裔血液及肿瘤专家学会

2022 New York Oncology Forum

Saturday, October 8, 8:00 am – 5:00 pm

Sunday, October 9, 8:30 am – 12:00 pm

Westchester Marriott
670 White Plains Rd
Tarrytown, NY 10591

CONFERENCE CHAIRS

Delong Liu, MD, PhD
New York Medical College

Yiwu Huang, MD, PhD
Maimonides Medical Center

www.cahon.org

SPONSORS & EXHIBITORS

2022 Corporate Partners



Gold Sponsor



Silver Sponsor



Bronze Sponsors



Exhibitors

AbbVie

Agios Pharmaceuticals

Alexion

AstraZeneca

AVEO Oncology

EMD Serano

Foundation Med

Genentech

Incyte Corp.

Janssen Biotech

Kadmon

Merck

Novartis

Pfizer

Sanofi

Seagen

Sobi

Stemline Therapeutics

Taiho Oncology

Takeda

**CANCER HAS
NO BORDERS.
NEITHER
DO WE**

Our mission is patients first through science and affordability. To help transform the biotechnology industry, creating impactful medicines that will be affordable and accessible to far more cancer patients around the world through science and business innovation.

8,000+

employees
(as of January 2022)

30+

filed or potentially registration
enabling trials ongoing, **95+** studies
in **40+** geographies

~50

commercial or clinical
stage assets

30

offices on
5 continents

20+

filings accepted for **10** medicines in
over **50** geographies, including 2nd
drug in U.S. and first in E.U.

9

approved medicines,
including **1** in the US

CONTENTS

Event Sponsors	Inside Cover
About CAHON	page 2
Upcoming CAHON Events	page 2
Meeting Agenda	page 4 & 5
About Our Speakers	page 7 & 8



ABOUT CAHON

Founded by Chinese American Hematologists and Oncologists in 2005, the primary missions of CAHON are to foster communications amongst Chinese American medical professionals for the delivery of high-quality health care to patients with neoplastic and hematological diseases, and to promote medical information exchange between the United States and China in the field of hematology and oncology. CAHON strives to serve as a bridge among its members and between Chinese and American Hematology-Oncology communities for medical and educational exchange.

THE STORY BEHIND THE LOGO

CAHON'S logo was designed by Drs. Weijing Sun, Ke Liu, and Jeffrey Ye, under the supervision of the CAHON Board. The design has the following elements and takes the following considerations:

- The overall shape represents the globe.
- The blue, white, red and yellow represent the colors of two nations' flags. China and the US.
- The yellow and red stripes above the blue, represent bridges. One of CAHON's key missions is to serve as a bridge between Chinese American Hematology-Oncology communities for medical and educational exchange.
- The white space is in the shape of a heart. The hearts of our members continue to drive our mission to provide high quality patient care to everyone.

CAHON MEMBERSHIP

Apply to become a CAHON Membership at cahon.org

VALUE OF A CAHON MEMBERSHIP

By joining CAHON you will have access to:

- A growing network of Chinese American professionals working in your field;
- A private WeChat group where you can submit clinical questions to respected colleagues who are knowledgeable in specific areas of hematology and oncology;
- Reduced or waived registration fees for all CAHON events and meetings along with priority hotel reservations;
- Members-only section of the CAHON website featuring the member directory; and
- Travel award opportunities.

MEMBERSHIP CATEGORIES

Regular/Active Membership

Associate Membership

Allied Membership

Visit cahon.org/membership for more information on membership.

SAVE THE DATE!

2022 Winter Symposium and Reception

December 10, 2022

New Orleans, LA



Nasopharyngeal carcinoma (NPC):

FACING THE SURVIVAL FACTS

HEAD AND NECK CANCERS
**1-YEAR
PROGRESSION-FREE
SURVIVAL**

20%

R/M NASOPHARYNGEAL ^{1*}

METASTATIC
OROPHARYNGEAL ^{2†}

76%
HPV+

39%
HPV-

91% STAGE IV
LARYNGEAL ^{3‡}

SEE THE
**NPC
FACTS**



NPCFacts.com/summer

Nasopharyngeal carcinoma (NPC) is a distinct cancer with a unique etiology and prognosis. Progression-free survival and overall survival data show poor outcomes in recurrent/metastatic disease, and limited effective treatment options highlight an unmet need in this area.

HPV = human papillomavirus, R/M = recurrent/metastatic.

*Results from a multicenter, randomized, open-label phase 3 trial of patients with recurrent or metastatic nasopharyngeal carcinoma (N=362).

†Results from a retrospective analysis of patients with HPV-positive and HPV-negative recurrent locoregional and distant metastatic oropharyngeal cancer (N=108).

‡Results from a retrospective study of patients with laryngeal squamous cell carcinoma (N=211).

References: 1. Zhang L, et al. *Lancet*. 2016;388:1883-1892. 2. Guo T, et al. *Cancer*. 2015;121:1977-1984. 3. Zhang Q, et al. *Front Oncol*. 11:606010.



© 2022 Coherus BioSciences, Inc.
All rights reserved. 0422-IO-P165

Meeting Agenda

3.25 hours of AMA PRA Category 1 Credit(s)TM

11:30 am – 1:00 pm	On-site Registration, Exhibitors Visitation
1:00 pm	Opening Remarks Bo Zhao, MD – CAHON President, <i>Virginia Oncology Associates</i> Fengting Yan, MD, PhD – <i>Swedish Cancer Institute</i>
1:05 – 1:35 pm	Keynote Speech: Progress in Hematopoietic Stem Cell Transplantation Speaker: Frederick Appelbaum, MD – <i>Fred Hutchinson Cancer Research Center</i> Moderator: Jing-Zhou Hou, MD, PhD – <i>University of Pittsburgh</i>
1:35 – 1:55 pm	Update of AML/MDS Management Speaker: Hongtao Liu, MD, PhD – <i>University of Chicago</i> Moderator: Delong Liu, MD, PhD – <i>New York Medical College</i>
1:55 – 2:15 pm	Update of Multiple Myeloma Management Speaker: Jing Christine Ye, MD – <i>University of Michigan</i> Moderator: Min Yan, MD – <i>Epic Care</i>
2:15 – 2:35 pm	Update of Molecular Diagnosis in Lymphoma Speaker: Linsheng Zhang, MD, PhD – <i>Emory University</i> Moderator: Xueyan Chen, MD, PhD – <i>University of Washington Medical Center</i>
2:35 – 2:55 pm	Coffee Break & Visit the Exhibitors
2:55 – 3:15 pm	Update of GU Cancer Management Speaker: Song Zhao, MD, PhD – <i>Swedish Cancer Institute</i> Moderator: Jingsong Zhang, MD, PhD – <i>Moffit Cancer Center</i>
3:15 – 3:35 pm	Roundtable Discussion of Breast Cancer Management Panelists: Iris Zhi, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i> Min Sun, MD, PhD – <i>University of Pittsburgh</i> Faye Yin, MD – <i>Florida Cancer Specialists</i> Wendy Wang, MD, PhD – <i>The Everett Clinic</i> Xuan Huang, MD, PhD – <i>University Hospitals of Cleveland</i> Wenqing Zhang, MD, PhD – <i>Florida Cancer Specialists</i>
3:35 – 3:55 pm	Roundtable Discussion of Lung Cancer Management Panelists: Tianhong Li, MD, PhD – <i>UC Davis Cancer Center</i> Spring Kong, MD, PhD – <i>University of Hong Kong</i> Yong Ji, MD, PhD – <i>Penn Medicine</i> Jane Liu, MD – <i>Illinois Cancer Care</i> Ligeng Tian, MD, PhD – <i>Virginia Oncology Associates</i> Sarah Wang, MD – <i>Parkview Health</i>
3:55 – 4:15 pm	Roundtable Discussion of GI Cancer Management Panelists: Weijing Sun, MD – <i>The University of Kansas Medical Center</i> Ping Gu, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i> Jiping Wang, MD, PhD – <i>Dana-Farber Cancer Institute</i> Lei Zheng, MD, PhD – <i>John Hopkins University School of Medicine</i> Yuxia Jia, MD, PhD – <i>FDA</i> Henry Xiong, MD, PhD – <i>The Center for Cancer and Blood Disorders, TX</i>
4:15 – 4:35 pm	Coffee Break & Visit the Exhibitors
4:35 – 4:55 pm	The Economics of Hematology/Oncology Practice: An Overview of the Ever-Changing Financial Landscape Speaker: Peter Y.Z. Jiang, MD, PhD – <i>The Everett Clinic</i> Moderator: David Chang, MD, PhD – <i>Virginia Oncology Associates</i> Panelists: Yiwu Huang, MD, PhD – <i>Maimonides Medical Center</i> Ying Zhuo, MD, PhD – <i>Kadlec Clinic</i> Joyce Huang, MD, PhD – <i>Cancer Care Associates of York</i> Lai (Amber) Xu, MD, PhD – <i>Northwest Oncology & Hematology</i> Peter Q. Jiang, MD, PhD – <i>John B. Amos Cancer Center</i> Bo Wang, MD – <i>Willamette Valley Cancer Institute and Research Center</i> Vicky Lee, MD, PhD – <i>Legacy Cancer Institute</i> Amanda Sun, MD, PhD – <i>Kaiser Permanente WA</i> Kaihong Mi, MD, PhD – <i>UPMC Hillman Cancer Center-Pinnacle</i>
4:55 – 5:00 pm	Closing Remarks Wenru Song, MD, PhD, CAHON Immediate Past Board Chair
7:00 – 8:00pm	CAHON Members Reception

Meeting Agenda

3.25 hours of AMA PRA Category 1 Credit(s)TM

11:30 am – 1:00 pm	On-site Registration, Exhibitors Visitation
1:00 pm	Opening Remarks Bo Zhao, MD – CAHON President, <i>Virginia Oncology Associates</i> Fengting Yan, MD, PhD – <i>Swedish Cancer Institute</i>
1:05 – 1:35 pm	Keynote Speech: Progress in Hematopoietic Stem Cell Transplantation Speaker: Frederick Appelbaum, MD – <i>Fred Hutchinson Cancer Research Center</i> Moderator: Jing-Zhou Hou, MD, PhD – <i>University of Pittsburgh</i>
1:35 – 1:55 pm	Update of AML/MDS Management Speaker: Hongtao Liu, MD, PhD – <i>University of Chicago</i> Moderator: Delong Liu, MD, PhD – <i>New York Medical College</i>
1:55 – 2:15 pm	Update of Multiple Myeloma Management Speaker: Jing Christine Ye, MD – <i>University of Michigan</i> Moderator: Min Yan, MD – <i>Epic Care</i>
2:15 – 2:35 pm	Update of Molecular Diagnosis in Lymphoma Speaker: Linsheng Zhang, MD, PhD – <i>Emory University</i> Moderator: Xueyan Chen, MD, PhD – <i>University of Washington Medical Center</i>
2:35 – 2:55 pm	Coffee Break & Visit the Exhibitors
2:55 – 3:15 pm	Update of GU Cancer Management Speaker: Song Zhao, MD, PhD – <i>Swedish Cancer Institute</i> Moderator: Jingsong Zhang, MD, PhD – <i>Moffit Cancer Center</i>
3:15 – 3:35 pm	Roundtable Discussion of Breast Cancer Management Panelists: Iris Zhi, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i> Min Sun, MD, PhD – <i>University of Pittsburgh</i> Faye Yin, MD – <i>Florida Cancer Specialists</i> Wendy Wang, MD, PhD – <i>The Everett Clinic</i> Xuan Huang, MD, PhD – <i>University Hospitals of Cleveland</i> Wenqing Zhang, MD, PhD – <i>Florida Cancer Specialists</i>
3:35 – 3:55 pm	Roundtable Discussion of Lung Cancer Management Panelists: Tianhong Li, MD, PhD – <i>UC Davis Cancer Center</i> Spring Kong, MD, PhD – <i>University of Hong Kong</i> Yong Ji, MD, PhD – <i>Penn Medicine</i> Jane Liu, MD – <i>Illinois Cancer Care</i> Ligeng Tian, MD, PhD – <i>Virginia Oncology Associates</i> Sarah Wang, MD – <i>Parkview Health</i>
3:55 – 4:15 pm	Roundtable Discussion of GI Cancer Management Panelists: Weijing Sun, MD – <i>The University of Kansas Medical Center</i> Ping Gu, MD, PhD – <i>Memorial Sloan Kettering Cancer Center</i> Jiping Wang, MD, PhD – <i>Dana-Farber Cancer Institute</i> Lei Zheng, MD, PhD – <i>John Hopkins University School of Medicine</i> Yuxia Jia, MD, PhD – <i>FDA</i> Henry Xiong, MD, PhD – <i>The Center for Cancer and Blood Disorders, TX</i>
4:15 – 4:35 pm	Coffee Break & Visit the Exhibitors
4:35 – 4:55 pm	The Economics of Hematology/Oncology Practice: An Overview of the Ever-Changing Financial Landscape Speaker: Peter Y.Z. Jiang, MD, PhD – <i>The Everett Clinic</i> Moderator: David Chang, MD, PhD – <i>Virginia Oncology Associates</i> Panelists: Yiwu Huang, MD, PhD – <i>Maimonides Medical Center</i> Ying Zhuo, MD, PhD – <i>Kadlec Clinic</i> Joyce Huang, MD, PhD – <i>Cancer Care Associates of York</i> Lai (Amber) Xu, MD, PhD – <i>Northwest Oncology & Hematology</i> Peter Q. Jiang, MD, PhD – <i>John B. Amos Cancer Center</i> Bo Wang, MD – <i>Willamette Valley Cancer Institute and Research Center</i> Vicky Lee, MD, PhD – <i>Legacy Cancer Institute</i> Amanda Sun, MD, PhD – <i>Kaiser Permanente WA</i> Kaihong Mi, MD, PhD – <i>UPMC Hillman Cancer Center-Pinnacle</i>
4:55 – 5:00 pm	Closing Remarks Wenru Song, MD, PhD, CAHON Immediate Past Board Chair
7:00 – 8:00pm	CAHON Members Reception



we bring
something rare
to rare diseases



At Sobi, we're dedicated to transforming the lives of people with rare diseases. This is why we specialise in rare diseases, in developing ground-breaking treatments, and in strong partnerships with patients and other stakeholders.

sobi.com



Sobi and Rare Strength are trademarks of Swedish Orphan Biovitrum AB (publ). © 2022 Swedish Orphan Biovitrum AB (publ) – All rights reserved
Swedish Orphan Biovitrum AB (publ) SE-112 76 Stockholm, Sweden +46(0)8 697 20 00
Date of preparation: Month Year, NP:XXX

Speakers

Sundar Jagannath, MD



Dr Jagannath is the Director of the Multiple Myeloma Center of Excellence at Tisch Cancer Institute, Mount Sinai Hospital, New York, NY. He is also Professor of Medicine and Mount Sinai Endowed Chair for Multiple Myeloma at Mount Sinai School of Medicine.

A renowned expert in Multiple Myeloma and Bone Marrow Transplantation, Dr Jagannath has published extensively on these topics and is often an invited presenter at professional organizations' annual meetings. He is editor-in-chief of *Clinical Lymphoma, Myeloma & Leukemia* and a peer reviewer for many other journals. Dr Jagannath is a board member for the Society of Hematologic Oncology. He is an active member of the American Society of Clinical Oncology and the American Society of Hematology. In 2003, Dr Jagannath received the Humanitarian Award from the Multiple Myeloma Research Foundation, and in 2006, 2009, and 2010 he was the recipient of the Foundation's Laugh for Life Award. In 2017, Dr. Jagannath received the Innovator Award from the Multiple Myeloma Research Consortium (MMRC). Most recently, Dr. Jagannath received the 2018 Fellow of the American Society of Clinical Oncology Award (FASCO).

Jingsong Zhang, MD, PhD



Dr. Zhang is a Genitourinary Oncologist and Interim Vice Chair, Department of Genitourinary Oncology at Moffitt Cancer Center, as well as an Associate Professor of Oncology and Internal Medicine at the University of South Florida College of Medicine. His primary research

interest is in integrating tumor evolution dynamics into the treatment for advanced prostate cancer. As the clinical research director of Moffitt cancer center's genitourinary oncology program, he has been the principal Investigator (PI) and co-investigator of > 50 phase I, II and III clinical studies since joining Moffitt in July 2010. He is also the co-investigator on R21, R01, U01, U54 grants to study adaptive androgen deprivation therapy and immunotherapy in metastatic prostate cancer.

Alan Ho

Elizabeth Budde



Dr. Elizabeth Budde is a well-recognized clinical expert and researchers in the area of blood cancers. Her academic and clinical interests center on novel treatment for patients with lymphoma and leukemia. As a physician scientist, she leads a group of researchers in her laboratory

designing and investigating the use of immunotherapy to treat blood cancers and other diseases.

She leads the Immunotherapy Modality Team and chairs the Clinical Cellular Immunotherapy Committee at the institution.

She also serves as a member on several national committees including National Comprehensive Cancer Network (NCCN) guidelines for B Cell Lymphoma, NCCN guidelines for Management of Immunotherapy-related Toxicities, and Alliance of American Cancer Institute CAR T Working Group.

Dr. Budde has received many honors and awards for her work. She was chosen as a Special Fellow in Clinical Research awardee by The Leukemia & Lymphoma Society, and an awardee of the Stop Cancer Foundation seed grant in 2016. She is also a recipient of the prestigious Damon Runyon Cancer Research Foundation Clinical Investigator Award (2014-2019). She has published many peer-reviewed articles that have been featured in prominent journals including the Journal of Clinical Oncology, Blood, Clinical Cancer Research, Journal of Immunology. She has also given many invited presentations at national and international meetings on her work.

Dr. Budde holds patents for new drugs currently under development in lymphoma and leukemia. She is the principal investigator of innovative translational research protocols and maintains a dynamic portfolio of clinical trials. Dr. Budde is devoted to making promising new treatments available to all her patients.

Jing-Zhou Hou



Dr. Jing-Zhou Hou obtained a degree of Bachelor of Medicine from Zhengzhou University (Henan Medical University), a degree of Master of Medical Science from Fudan University (previously Shanghai Medical University), and a PhD in Molecular and Cellular Biology from

Tulane University. Subsequently, he studied apoptosis and its relationship with resistance to chemotherapy in lymphoma cells at National Cancer Institute (NCI, NIH). Dr. Hou completed clinical training in Internal Medicine residency at Northeastern Ohio Universities College of Medicine.

Having had strong interest in hematology and hematological malignancies, Dr. Hou chose and completed his clinical fellowship in Hematology and Medical Oncology at Stanford University. He then continued his clinical and translational research in the division of Blood and Marrow Transplantation at Stanford University School of Medicine. Specifically, he characterized the human T regulatory (Treg) cells from the allogeneic hematopoietic stem cell donors, developed a strategy to purify human Treg in high purity and quantity from these donors for clinical prevention and treatment of acute graft versus host diseases (GVHD). Dr. Hou also has strong research interest in lymphomas and immunotherapy.

Dr. Hou joined Hillman Cancer Center, the flagship cancer center of University of Pittsburgh Medical Center (UPMC) Cancer Centers (the second largest cancer center network in the US) in 2007. Dr. Hou is a clinician and clinical investigator in hematology and BMT. He attends inpatient and outpatient Leukemia/Hematology service and BMT services. He

Speakers

collaborates with laboratory scientist/investigators at University of Pittsburgh Cancer Institute on translational research in immune and cellular therapy in hematological malignancies and BMT. Dr. Hou is board certified in Internal Medicine and Hematology.

Dr. Hou serves as the chair of the lymphoma pathway committee at UPMC Cancer Centers. The committee is responsible to develop a single best modality/regimen for different types of Hodgkin's Lymphoma and Non-Hodgkin's Lymphomas basing on the best available clinical evidences after vigorous internal review and debate. Dr. Hou also serves in the Protocol Scientific Review Committee for UPMC Cancer Centers, and actively participates in the various clinical educational activities for fellows, residents, and medical students. Dr. Hou has been a member of CAHON since its birth.

Cynthia Ma



Dr. Cynthia Ma is a breast oncologist and a physician scientist, with research focuses on endocrine therapy and targeted agents for the treatment of breast cancer. She has led several biomarker directed, investigator initiated trials including neoadjuvant studies of endocrine

agents in combination with inhibitors against PI3K pathway or the CDK4/6 in patients with locally advanced estrogen receptor positive breast cancer. She is the study chair for the ongoing ALLIANCE ALTERNATE trial, which evaluates Ki67 based biomarkers as well as genomic predictors of endocrine responsiveness. She is the clinical director of the Breast Cancer Program in Medical Oncology at Washington University School of Medicine and a member of the Alliance Breast Committee.

Jingquan Jia, MD

Assistant Professor at Duke University Cancer Center



Dr. Jingquan Jia is an Assistant Professor at Duke University Cancer Center subspecializing in GI malignancies. She earned his medical degree from Beijing Medical University and PhD. Degree in Immunology from Duke University. After completing internal medicine residency at

Eastern Carolina University in 2016, she returned to Duke for hematology oncology fellowship and stayed on as faculty. Dr Jia's clinical and academic research is focused on the multidisciplinary approach to the treatment of patients with hepatobiliary tumors as well as correlative biomarker research in GI malignancies. She has been the principal investigator for several investigator-initiated clinical trials focusing on immunotherapy and precision medicine and received a grant from Mario Family Foundation to further her research. She has presented her research in national meetings and has authored or co-authored multiple articles focused on gastrointestinal cancers in peer-reviewed journals. She is a member of the ASCO Scientific Program Committee.

Notes



Takeda is a global, R&D-driven biopharmaceutical company committed to discovering and delivering life-changing treatments and vaccines that have a lasting impact on society.

Since our founding in 1781 in a market stall in Osaka, Japan, our values endure by putting patient needs first, building trust with society, strengthening our reputation, and developing the business—in that order.

www.takeda.com
US-NON-8223v1.0 8/22



Notes



OurLenvima.com

A valuable education resource
for your patients

Available in the following languages:

English

Chinese

Korean

Spanish

Vietnamese



LENVIMA® is a registered trademark by Eisai Inc. under license from Eisai R&D Management Co. Ltd

© 2021 Eisai Inc.


All rights reserved.

May 2021

LENV-US5758

Notes

Transforming
patients' lives
through science™

 Bristol Myers Squibb™

Visit bms.com to see how we're bringing a human touch to everything we do.

© 2020 Bristol Myers Squibb Company. All rights reserved.



Orelabrutinib – Potential Best-in-Class BTK Inhibitor

- **Orelabrutinib demonstrates compelling efficacy**
 - In 80 patients with R/R CLL, at median follow-up of 32.3 months, ORR was 93.8%, CR was 24%, CRi was 2%. mDoR NR
 - In 99 patients with R/R MCL, at median follow-up of 23.8 months, ORR was 88%, CR was 37%, mDoR was 26-mo
- **Orelabrutinib shows class leading safety and tolerability in patients with various b-cell malignancies**
 - No case of ≥3 Grade 3 A-fib, rare case of major bleeding/severe hypertension/diarrhea
 - Most common AE are Grade 1-2, occurring during the early course of treatment
 - 5% of patients discontinued treatment due to AE, 2% were treatment related
- **Orelabrutinib has demonstrated similar efficacy and safety profile in US patients**
- **Orelabrutinib has been granted Breakthrough Therapy Designation for r/r MCL indication by the FDA**
- **We are recruiting BTKi treatment naïve r/r MCL patients for our US registration study**



Scan the QR code or visit
TAVALISSEhcp.com to learn about
a different approach to treatment.

Tavalisse
(fostamatinib disodium
hexahydrate) tablets

© 2022 Rigel Pharmaceuticals, Inc. All rights reserved. TAVA-ITP-22158 0822
TAVALISSE is a registered trademark of Rigel Pharmaceuticals, Inc.



A powerful way to fight cancer lives inside your body.

To fight cancer, we are developing immunotherapies that work with the body's natural defenses. Helping us get closer to a future where disease is a thing of the past. Learn more at www.janssen.com.

janssen Oncology
PHARMACEUTICAL COMPANIES OF **Johnson & Johnson**

Explore the clinical profile of LIBTAYO across multiple indications

Visit LIBTAYOhcp.com to learn more



REGENERON | SANOFI GENZYME 

© 2021 Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. All rights reserved. LIB.21.03.0143 03/21


LILLY FOR BETTER

The human race has always been curious, hopeful and resilient. Discovery is our purpose on this planet. It's our calling and the spirit that's defined Lilly since day one. After more than a century and nearly 100 medicines and countless innovations, we're still searching for the next great discovery that will make life better for people around the world.

Lilly

lilly.com

2020 CA Approved for External Use PRINTED IN USA ©2020, Eli Lilly and Company. ALL RIGHTS RESERVED.





Chinese American Hematologist and Oncologist Network (CAHON)

555 East Wells Street, Suite 1100 • Milwaukee, WI 53202 USA

Phone: 1 414-918-9890 • Fax: 1 414-276-3349